Despite advancements in conventional therapies, many individuals with Crohn’s disease continue to experience severe inflammation and complications. This has led to increasing interest in umbilical cord-derived mesenchymal stem cells (UC-MSCs) as a potential treatment. Unlike other stem cell sources, UC-MSCs are easily obtained, exhibit strong immunomodulatory properties, and have low immunogenicity, reducing the risk of rejection.
One of the key aspects under investigation is dosage and administration. Clinical studies have explored various protocols, with IV infusion being the most common method. Typical dosing falls within 1–2 million cells per kilogram of body weight, administered over multiple sessions. Localized delivery methods, such as endoscopic injections, are also being studied for their potential to directly target inflamed areas of the gastrointestinal tract.
The safety profile of UC-MSC therapy has been encouraging, with most adverse effects being mild and transient. Reported benefits include reduced inflammation, improved bowel function, and a decreased need for immunosuppressive medications.
As clinical trials progress, UC-MSC therapy could become a valuable addition to Crohn’s disease treatment options.
